Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. In this article, we report on old and new therapeutic strategies that proved effective in early preclinical and clinical trials, and subsequently in the daily clinical practice, for patients with MF, particularly concerning the topics of anaemia, splenomegaly, iron overload, and allogeneic stem cell transplantation.

Treatment of myelofibrosis: Old and new strategies / A. Iurlo, D. Cattaneo. - In: CLINICAL MEDICINE INSIGHTS. BLOOD DISORDERS. - ISSN 1179-545X. - 10(2017), pp. 1-10. [10.1177/1179545X17695233]

Treatment of myelofibrosis: Old and new strategies

D. Cattaneo
2017

Abstract

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. In this article, we report on old and new therapeutic strategies that proved effective in early preclinical and clinical trials, and subsequently in the daily clinical practice, for patients with MF, particularly concerning the topics of anaemia, splenomegaly, iron overload, and allogeneic stem cell transplantation.
myeloproliferative neoplasms; myelofibrosis; JAK2 inhibitors; ruxolitinib; momelotinib; allogeneic stem cell transplant
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
Iurlo A et al. Clin Med Insights Blood Disord 2017.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 504.17 kB
Formato Adobe PDF
504.17 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/859492
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
social impact